Brian Markison

Chief Executive Officer (CEO) at Lantheus Holdings

Board

Since March 1, 2024

Age

64 years

Education

Holds a Bachelor of Science degree from Iona College.

Tenure

Joined LNTH as a member of the Board of Directors in September 2012, became Chairperson in January 2013, and assumed the CEO role on March 1, 2024.

Also at Lantheus Holdings

Amanda Morgan

Chief Commercial Officer (CCO)

DMN

Daniel M. Niedzwiecki

Chief Administrative Officer, General Counsel, and Corporate Secretary

DJP

Dr. Jean-Claude Provost

Chief Science Officer (CSO)

About

Brian Markison has built an impressive career in the pharmaceutical and healthcare industries over the past 40 years, demonstrating extensive expertise in operational management, marketing, and commercial development. His solid academic foundation, highlighted by earning a Bachelor of Science degree, has been complemented by hands-on leadership roles at prominent organizations in the sector.

Throughout his career, he has taken on progressively important roles, serving in senior positions at companies such as Bristol-Myers Squibb, King Pharmaceuticals, Fougera Pharmaceuticals, and RVL Pharmaceuticals. His experience ranges from leading product introductions to executing strategic operational initiatives, positioning him as a notable figure in the industry.

At LNTH, his journey has been marked by significant milestones. Initially joining the Board of Directors in September 2012, he advanced to Chairperson in January 2013 and ultimately assumed the role of Chief Executive Officer on March 1, 2024. His contributions in steering the company’s strategy and overseeing a smooth leadership transition underscore his dedication to fostering growth and innovation within the organization.

$LNTH Performance Under Brian Markison

Past Roles

Organization	Role	Date Range	Details
Lantheus Holdings (LNTH)	Executive Chairman	January 23, 2024 – March 1, 2024	Served until his appointment as CEO
Lantheus Holdings (LNTH)	Non-Executive Chairman of the Board	September 2012 – January 23, 2024	Joined Board in September 2012 and elevated to Chairman in January 2013
Fougera Pharmaceuticals Inc.	President and Chief Executive Officer	N/A	Company was sold to Sandoz, the generics division of Novartis AG
King Pharmaceuticals	Chief Operating Officer, President, Chief Executive Officer, and Chairman	2004 – N/A	Joined as COO in March 2004, promoted to President and CEO later in 2004, and elected Chairman in 2007
Bristol-Myers Squibb	Various Senior Leadership Positions	N/A	Held roles including President of Oncology, Virology, and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease, and Dermatology; and Senior Vice President, Operational Excellence and Productivity

External Roles

Organization	Role	Date Range
RVL Pharmaceuticals plc	Chief Executive Officer and Director	Current
The College of New Jersey	Director	Current
Cosette Pharmaceuticals	Board Member	Current